|1.||Plunkett, William: 5 articles (08/2012 - 08/2005)|
|2.||Liu, Xiaojun: 4 articles (04/2012 - 08/2005)|
|3.||Matsuda, Akira: 4 articles (09/2010 - 06/2002)|
|4.||Matsuda, A: 3 articles (06/2001 - 01/2001)|
|5.||Kantarjian, Hagop: 2 articles (04/2012 - 09/2010)|
|6.||Skierski, Janusz S: 2 articles (07/2004 - 05/2004)|
|7.||Szafraniec, Sylwia I: 2 articles (07/2004 - 05/2004)|
|8.||Stachnik, Krzysztof J: 2 articles (07/2004 - 05/2004)|
|9.||Oku, Naoto: 2 articles (01/2004 - 06/2002)|
|10.||Ogino, Koichi: 2 articles (01/2004 - 06/2002)|
01/16/1998 - "2'-C-Cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is an antitumor nucleoside with a novel chemical structure that exerts potent antitumor activity against various human tumor cells in vitro and in vivo. "
01/01/1996 - "CNDAC had potent antitumor effects against various solid tumors in vitro as well as in vivo. "
01/01/1996 - "[Design of a new antitumor nucleoside CNDAC, against solid tumors]."
05/30/1992 - "Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors."
07/01/1998 - "DPP-CNDAC showed suppression of tumor growth, whereas CNDAC did not at the same concentration, suggesting that 5'-phosphatidylation is useful to enhance therapeutic efficacy. "
01/16/1998 - "We induced resistance to CNDAC in the human fibrosarcoma cell line HT-1080 by exposure to increasing concentrations of CNDAC. "
01/16/1998 - "Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080."
05/30/1992 - "Characteristically CNDAC showed excellent activities against tumors, refractory to ara-C, such as HT-1080 human fibrosarcoma implanted in chick embryos or athymic mice, although its cytotoxicity against HT-1080 was almost equal to that of ara-C. "
05/30/1992 - "Compared with ara-C, CNDAC was more effective in 10 human tumors (2 lung, 4 stomach and 4 osteosarcoma), equal in 2 tumors (lung and fibrosarcoma) and less potent in 11 tumors (4 lung, 4 osteosarcoma, bladder, renal and epidermoid). "
|3.||Osteosarcoma (Osteogenic Sarcoma)
|4.||Hematologic Neoplasms (Hematological Malignancy)
08/01/2005 - "These findings provide a mechanistic rationale for the design of new strategies, combining CNDAC with inhibitors of cell cycle checkpoint regulation in the therapy of hematologic malignancies."
09/09/2010 - "The nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosyl-cytosine (CNDAC), currently in clinical trials for hematologic malignancies, has a novel action mechanism of causing a single-strand break after its incorporation into DNA. "
05/01/2004 - "In this paper we describe mechanisms of action and possible clinical use in the treatment of hematological malignancies of these nucleoside analogs, which are now in different stages of clinical trials, namely tezacitabine, troxacitabine, clofarabine, nelarabine, decitabine, CNDAC and ECyD."
06/15/2001 - "The pharmacokinetics and pharmacodynamics of the novel clinical candidate 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) were investigated in human lymphoblastoid CCRF-CEM cells and human myeloblastic leukemia ML-1 cells. "
04/01/2001 - "The mechanism of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human lymphoblastoid CEM cells and myeloblastic leukemia ML-1 cells. "
06/15/2001 - "Thus, the ability of human leukemia cells to effectively accumulate and retain CNDACTP, coupled with the favorable kinetics of competition for incorporation into DNA, and the relatively strong ability of the analog to terminate further extension, are likely to contribute to the cytotoxic action of CNDAC."
|3.||DNA (Deoxyribonucleic Acid)
|5.||2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731)
|1.||Heterologous Transplantation (Xenotransplantation)